FDA Accepts Application for Gazyva® (obinutuzumab) to Treat SLE
The U.S. Food and Drug Administration has accepted the supplemental Biologics License Application from Genentech for Gazyva® (obinutuzumab) to treat systemic lupus erythematosus (SLE), the most common form of...
